Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- 5 Companies Find 46 Unreported ADR Cases as a Result of Self-Inspections
September 3, 2015
- Ryukaikon Calls for Elimination of Medical Fee Cut Rule for Low Price Settlement Rates Once Early Price Settlements Are Achieved
September 2, 2015
- Ryukaikon Submits New Proposal to Improve Drug Distribution Environment
September 2, 2015
- AbbVie’s Hep C Drug OK’ed by PAFSC Committee, Setting Stage for Competition with Harvoni
September 1, 2015
- PAFSC First Committee Backs Approval of Glatiramer, Add’l Indication for Xarelto
August 31, 2015
- FY2016 Budget Request to Earmark 151.5 Billion Yen for AMED, with 25.3 Billion Yen for Drug Discovery and Development
August 31, 2015
- METI Seeks 126.9 Billion Yen in FY2016 Budget for Science, Technology Promotion, 21.2 Billion Yen for AMED
August 31, 2015
- MEXT Seeks 5.86 Trillion in FY2016 Budget for “Innovative Drug Discovery for Cancer”
August 31, 2015
- Chuikyo Rep Nakagawa Casts Doubt on 80% Generic Target
August 28, 2015
- MHLW Panel Recommends Creation of Database on Rare Cancers by Type
August 28, 2015
- MHLW Mulls Ordering Pfizer to Improve Biz Operations over ADR Reporting
August 28, 2015
- Panel OKs Medical Subsidy for Harvoni, Monthly Copay Up to 20,000 Yen
August 28, 2015
- Commentary: Spiking Drug Prices Behind Harvoni Pricing Spat at Chuikyo
August 28, 2015
- PFSB to Monitor Drug Companies’ Promotional Activities at 20 Selected Medical Facilities
August 28, 2015
- PFSB to Request Budget of 10.7 Billion Yen in FY2016 to Improve Environments for Development of Innovative Drugs, Quality of Generics
August 28, 2015
- Health Service Bureau Seeks 469.1 Billion Yen in FY2016 Budget, 120.2 Billion Yen for Intractable Diseases
August 28, 2015
- Health Policy Bureau Seeks 193.6 Billion Yen in FY2016 Budget, 6.6 Billion Yen for Clinical Research Promotion
August 28, 2015
- FPMAJ Wants Continuation of Innovation Premium, No Market Price-Based Price Revision in 2017: Chuikyo Hearings
August 27, 2015
- Chuikyo’s HTA Panel Issues Interim Report, Appraisal Results to Be Used to Re-Price Selected Listed Drugs
August 27, 2015
- Development Projects, Regulatory Filings Increasing Thanks to Innovation Premium: PhRMA, EFPIA
August 27, 2015
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…